WP
AUTL

Woodline Partners’s Autolus Therapeutics AUTL Stock Holding History

Woodline Partners’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-428,255
Closed -$916K – 759
2022
Q3 		$916K Sell
428,255
-297,859
-41% -$882K 0.01% 544
2022
Q2 		$2.06M Sell
726,114
-69,897
-9% -$213K 0.03% 418
2022
Q1 		$3.32M Sell
796,011
-141,950
-15% -$597K 0.05% 299
2021
Q4 		$4.87M Buy
+937,961
New +$5.63M 0.07% 285

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
OAMG
Odey Asset Management Group London, United Kingdom $381M AUM 45.36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Woodline Partners's AUTL Position: Q4 2022 in Review

Woodline Partners sold out of Autolus Therapeutics (AUTL) in Q4 2022, closing a stake of 428,255 shares — an estimated $916K sold.

Woodline Partners first reported a position in AUTL in Q4 2021 and held it in 4 quarters. The position peaked at $4.87M in Q4 2021. 71 funds tracked by Wall St. Rank hold AUTL as of Q4 2022.

  • Woodline Partners reported no remaining Autolus Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Woodline Partners sold 428,255 Autolus Therapeutics shares in Q4 2022, an estimated $916K.
  • Woodline Partners first reported a position in Autolus Therapeutics in Q4 2021 and held it in 4 quarters.
  • Woodline Partners's Autolus Therapeutics position peaked at $4.87M in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q4 2022.

Based on Woodline Partners's 13F filing for Q4 2022, filed 14 Feb 2023.